Validation of Ganoderma lucidum against hypercholesterolemia and Alzheimer’s disease

  • Mohammad Azizur Rahman Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh; Mushroom Research Centre, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
  • Md Shahdat Hossain Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh
  • Noorlidah Abdullah Mushroom Research Centre, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
  • Norhaniza Aminudin Mushroom Research Centre, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia; University of Malaya Centre for Proteomics Research, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Keywords: Alzheimer’s disease, Ganoderma lucidum, Hypercholesterolemia, Memory and learning, Protein markers of memory and learning

Abstract

Ganoderma lucidum has been hailed as medicinal mushroom. Its effect on memory and learning related behavioral performance along with related protein markers has been evaluated using Alzheimer’s disease (AD) and hypercholesterolemic model rats in the present study. AD model rats were prepared infusing amyloid beta peptide into the right ventricles of the rats. Hypercholesterolemia was evoked feeding 1% cholesterol and 1% cholic acid with basal diet of the rats for 8 weeks. Hot water extract of G. lucidum was ingested orally (200 mg/kg bw) to the HC and AD model rats. Memory and learning related behavioral tests were performed using Barnes maze while protein markers (BDNF, SNAP2, PSD-95, VAchT) were detected using ELISA. Observed findings suggest hypocholesterolemic, lipid profile improving and enhanced cognitive performance of the G. lucidum fed rats. Memory and learning related protein markers also substantiate this fruition. Thus, therapeutic potentiality of Ganoderma lucidum in AD amelioration seems promising.

DOI: http://dx.doi.org/10.5281/zenodo.4009588

Downloads

Download data is not yet available.

References

1. https://www.alz.co.uk/research/WorldAlzheimerReport2018.pdf?2

2. Hardy JA, Higgins GA. Alzheimer's Disease: The amyloid cascade hypothesis. Sci. 1992; 256: 184.

3. Michael SM, Jeffrey LC, Tara F, Jeffrey G. The spectrum of behavioral changes in Alzheimer's disease. Neurol. 1996; 46: 130-135.

4. Reisberg B, Borenstein J, Salob SP, Ferris SH. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiat. 1987; 48: 9-15.

5. Alzheimer’s Association. Alzheimer’s Association Report. Alzheimer’s disease facts and figures. Alzh Dement. 2018; 14: 367-429.

6. Sheraton M, Deo N, Kashyap R. A review of neurological complications of COVID-19. Cureus. 2020; 12(5): e8192.

7. Mielke MM, Jeannie-Marie L, Chris DC, Robert CG, Maria CN, Kathleen AWB, et al. Effects of FDA approved medications for Alzheimer’s disease on clinical progression. Alzh Dement. 2012; 8: 180-187.

8. Hamel E, Jessika R, Brice O, Xin-Kang T. Neurovascular and cognitive failure in Alzheimer’s disease: benefits of cardiovascular therapy. Cell Mol Neurobiol. 2016; 36: 219-232.

9. Reitz C. Dyslipidemia and the risk of Alzheimer’s disease. Curr Atheroscler Rep. 2013; 15: 307-313.

10. Sparks DL, Stephen W, Scheff JC, Hunsaker III, Huiachen L, Teresa L, David RG. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994; 126: 88-94.

11. Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas, Wang R, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000; 7: 690-691.

12. Refolo LM, Pappolla MA, LaFrancois, Malester J, Brian S, Stephen DJ, et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001; 8: 890-899.

13. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Ger Psychiat. 2001; 16: 343-354.

14. Mathew A, Yoshida YM, Kumar T, Sakthi D. Alzheimer's disease: Cholesterol a menace? Brain Res Bull. 2011; 86: 1-12.

15. DeKosky ST. Statin therapy in the treatment of Alzheimer disease: what is the rationale? Am J Med. 2005; 118(12): 48-53.

16. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000; 57(10): 1439-1443.

17. Fassbender K, Simons M, Bergmann C, Stroick M, Lütjohann D, Keller P, Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Nat Acad Sci. 2001; 98(10): 5856-5861.

18. Perk J, De Backer G, Gohlke H, Graham I, Riner Z, Cifkova, R. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012; 33(13): 1635-1701.

19. Rahman MA, Abdullah N, Aminudin N. Evaluation of the antioxidative and hypo-cholesterolemic effects of Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum (Agaricomycetes), in ameliorating cardiovascular disease. Int J Med Mushroom. 2018; 20(10): 961-969.

20. Rahman MA, Abdullah N, Aminudin N. Corroborative assessment of mushroom as the graceful ageing and lifespan promoting agent. Biointerf Res Appl Chem. 2017; 7(3): ID 2048.

21. Rahman MA, Abdullah N, Aminudin N. Ganoderma lucidum (P.) Karst modulates memory and learning related behaviour in Alzheimer's diseased rats. Behav Brain Res. 2017; 3(2): 45-55.

22. Rahman MA, Abdullah N, Aminudin,N. Ganoderma lucidum (P.) Karst ameliorates Alzheimer's diseased rat brain proteomics. J Proteom Res. 2017; 4(2): 152-161.

23. Rahman MA, Abdullah N, Aminudin N. Anti-oxidative and hypocholesterolemic potentiality of the solvent partitioned fractions of Ganoderma lucidum (Curtis) P. Karst (Lingzhi mushroom). Int J Med Mushroom. 2017.

24. Rahman MA, Abdullah N. Aminudin N. Interpretation of mushroom as a common therapeutic agent for Alzheimer’s disease and cardiovascular diseases. Crit Rev Biotechnol. 2015; 36(6): 1131-1142.

25. Yahaya NFM, Rahman MA, Abdullah N. Therapeutic potential of mushrooms in preventing and ameliorating hypertension. Trends Food Sci Technol. 2014; 39(2): 104-115.

26. Rahman MA, Abdullah N, Aminudin N. Lentinula edodes (shiitake mushroom): an assessment of in vitro anti-atherosclerotic bio-functionality. Saudi J Biol Sci. 2018; 25(8): 1515-1523.

27. Rahman MA, Abdullah N, Aminudin N. Antioxidative effects and inhibition of human low density lipoprotein oxidation in vitro of polyphenolic compounds in Flammulina velutipes (Golden Needle Mushroom). Oxid Med Cell Long. 2015: ID 403023.

28. Rahman MA, Abdullah N, Aminudin N. Inhibitory effect on in vitro LDL oxidation and HMG Co-a reductase activity of the liquid-liquid partitioned fractions of Hericium erinaceus (Bull.) persoon (Lion’s Mane Mushroom). BioMed Res Int. 2014: ID 828149.

29. Abdullah MA, Hashimoto M, Katakura M. Neuroprotective effect of madecassoside evaluated using amyloid Β1-42-mediated in vitro and in vivo Alzheimer’s disease models. Int J Ind Med Plant. 2014; 47: 1669-1682.

30. Otunola GA, Oloyede OB, Oladiji AT, Afolayan AA. Effects of diet-induced hypercholesterolemia on the lipid profile and some enzyme activities in female wistar rats. Afr J Biochem Res. 2010; 4(6): 149-154.

31. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atheroscler. 2002; 161(1): 1-16.

32. Baba S, Natsume M, Yasuda A. Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normo- and hypercholesterolemic humans after intake of different levels of cocoa powder. J Nutr. 2007; 137(6): 1436-1441.

33. Kaess BM, Preis SR, Lieb W, Beiser AS, Yang Q, Chen TC, et al. Circulating brain-derived neurotrophic factor concentrations and the risk of cardiovascular disease in the community. J Am Heart Assoc. 2015; 4(3): e001544.

34. Bahls M, Könemann S, Markus MRP, Wenzel K, Friedrich N, Nauck M, et al. Brain-derived neurotrophic factor is related with adverse cardiac remodeling and high NTproBNP. Sci Rep. 2019; 9(1): 15421.

35. Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem. 2002; 9(5): 224-237.

36. Siuda J, Patalong-Ogiewa M, Żmuda W, Targosz-Gajniak M, Niewiadomska E, Matuszek I, et al. Cognitive impairment and BDNF serum levels. Neurol Neurochir Pol. 2017; 51(1): 24-32.

37. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, et al. Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. PNAS. 2010; 107(5): 2295-2300.

38. Mizuno M, Yamada K, Olariu A, Nawa H, Nabeshima T. Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. J Neurosci. 2000; 20(18): 7116-7121.

39. Zhang XQ, Ip FC, Zhang DM, Chen LX, Zhang W, Li YL, et al. Triterpenoids with neurotrophic activity from Ganoderma lucidum. Nat Prod Res. 2011; 25(17): 1607-1613.

40. Gosso MF, de Geus EJC, van Belzen MJ, Polderman TJC, Heutink P, Boomsma DI, Posthuma D. The SNAP-25 gene is associated with cognitive ability: evidence from a family-based study in two independent Dutch cohorts. Mol Psychiat. 2006; 11: 878-886.

41. Greber S, Lubec G, Cairns N, Fountoulakis M. Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Electrophor. 1999; 20: 4-5, 928-934.

42. Musil R, Spellmann I, Riedel M. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatr Res. 2008; 42(12): 963-970.

43. Chen KH, Reese EA, Kim HW, Rapoport SI, Rao JS. Disturbed neurotransmitter transporter expression in Alzheimer disease brain. J Alzh Dis. 2011; 26(4): 755-756.

44. Sultana R, Banks WA, Butterfield DA. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: insights into their potential roles for loss of synapses and memory, accumulation of Aβ, and neurodegeneration in a prodromal stage of Alzheimer's disease. J Neurosci Res. 2010; 88(3): 469-477.

45. Ya BL, Liu WY, Ge F, Zhang YX, Zhu BL, Bai B. Dietary cholesterol alters memory and synaptic structural plasticity in young rat brain. Neurol Sci. 2013; 34(8): 1355-1365.

46. Fon Tacer K, Kuzman D, Seliskar M, Pompon D, Rozman D. TNF-alpha interferes with lipid homeostasis and activates acute and proatherogenic processes. Physiol Genomics. 2007; 31(2): 216-227.

47. Nguyen PA, Won JS, Rahman MK, Bae EJ, Cho MK. Modulation of Sirt1/NF-κB interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque formation. Biochem Pharmacol. 2019; 168: 452-464.

48. McAlpine FE, Lee JK, Harms AS, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009; 34(1): 163-177.

49. Rodrigues HA, Fonseca Mde C, Camargo WL, Lima PMA, Martinelli PM, Naves, LAP, Guatimosim C. Reduced expression of the vesicular acetylcholine transporter and neurotransmitter content affects synaptic vesicle de78342istribution and shape in mouse neuromuscular junction. PLoS One. 2013; 8(11): e78342.

50. Ullrich C, Pirchl M, Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci. 2010; 45(4): 408-417.

51. Prado VF, Martins-Silva C, de Castro BM, Lima RF, Barros DM. Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron. 2006; 51(5): 601-612.
Published
2020-08-31
How to Cite
(1)
Rahman, M.; Hossain, M.; Abdullah, N.; Aminudin, N. Validation of Ganoderma Lucidum Against Hypercholesterolemia and Alzheimer’s Disease. European Journal of Biological Research 2020, 10, 314-325.
Section
Research Articles